10 largest U.S. patent losses

In the drug business, exclusivity is everything. Once a branded drug gets generic competition, pricing power fades and sales slowly drain away, leaving drugmakers dependent on the next new thing. It's all very reasonable in theory, but when the drugs losing patent protection are the biggest in the business--and they're all falling off patent around the same time--even the most rational companies can get a bit panicky.

Welcome to the patent cliff, the most influential feature of today's pharma landscape. Here, so many drugs are falling off patent that the path forward has twisted, and the entire industry is looking to find its way. Some companies, such as Pfizer and Merck, have merged with major rivals. Others have snapped up acquisitions in ancillary businesses, such as generics and over-the-counter medicines, and expanded into countries they previously ignored. Still others have forged ahead, betting that they'd manage to develop enough new products to make up the difference. Click here to see report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.